Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mercadolibre Inc (MELI) vs Revvity Inc (RVTY) Price & Performance

Mercadolibre IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

Mercadolibre Inc vs Revvity Inc — how do they compare? Mercadolibre Inc trades at $1,936.99 (market cap $98.35B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Mercadolibre Inc is far larger — about 7.6× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.

MELIRVTY
Market Cap
$98.35B$12.91B
Sector
Consumer CyclicalTechnology
52-Week High
$2.51K$117.75
52-Week Low
$1.55K$82.26
Enterprise Value
$106.00B$15.23B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mercadolibre Inc

MercadoLibre (MELI) trades at $1,876, up 2.83% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 EPS of $9.19, beating estimates, while revenue grew 50% year-over-year to exceed $10 billion for the first time. Analyst consensus remains strongly bullish with 23 buy ratings and a $2,150 price target, though margin compression from strategic investments has tempered near-term profit growth.

MELI's growth-first strategy is driving market share gains but pressuring margins, creating a tension between rapid expansion and profitability. The stock offers significant upside to analyst targets but faces execution risks from increased competition and macroeconomic volatility in Latin America. Long-term investors may find value in the ecosystem growth, while short-term volatility could persist amid margin concerns.

Revvity Inc

RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.

The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mercadolibre Inc

MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.

Read more on MELI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY